<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский онкологический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1028-9984</issn><issn publication-format="electronic">2412-9119</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">685784</article-id><article-id pub-id-type="doi">10.17816/onco685784</article-id><article-id pub-id-type="edn">IGYERK</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Reviews</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Научные обзоры</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Ways to improve the results of conservative therapy of malignant tumors of the head and neck organs. Part II. Oropharyngeal Cancer (a review)</article-title><trans-title-group xml:lang="ru"><trans-title>Опухоли головы и шеи: пути улучшения результатов консервативной терапии. Часть II. Рак ротоглотки (обзор)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3219-1596</contrib-id><contrib-id contrib-id-type="spin">2467-6046</contrib-id><name-alternatives><name xml:lang="en"><surname>Kurpeshev</surname><given-names>Orazakhmet K.</given-names></name><name xml:lang="ru"><surname>Курпешев</surname><given-names>Оразахмет Керимбаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>д-р мед. наук</p></bio><email>kurpeshev-ok@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Siberian Research Institute of Hyperthermia</institution></aff><aff><institution xml:lang="ru">Сибирский научно-исследовательский институт гипертермии</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2026-01-12" publication-format="electronic"><day>12</day><month>01</month><year>2026</year></pub-date><pub-date date-type="pub" iso-8601-date="2026-02-14" publication-format="electronic"><day>14</day><month>02</month><year>2026</year></pub-date><volume>30</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>295</fpage><lpage>311</lpage><history><date date-type="received" iso-8601-date="2025-06-25"><day>25</day><month>06</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-10-18"><day>18</day><month>10</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Эко-Вектор</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2029-02-14"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://eco-vector.com/for_authors.php#07</ali:license_ref></license></permissions><self-uri xlink:href="https://rjonco.com/1028-9984/article/view/685784">https://rjonco.com/1028-9984/article/view/685784</self-uri><abstract xml:lang="en"><p>This review analyzes treatment outcomes in patients with locally advanced oropharyngeal squamous cell carcinoma. Despite the use of modern high-technology treatment modalities, management of this patient population remains a challenging clinical problem. As with other malignant tumors of the head and neck, the effectiveness of therapeutic approaches depends on multiple factors, including disease stage, tumor localization, treatment modality, HIV status, and other clinical variables. Surgical and reconstructive procedures are not indicated for most patients, which is attributable to the complex anatomical structure of the oropharyngeal region and the severe general condition of patients due to advanced disease. Therefore, conservative treatment modalities are preferable in the majority of cases, including radiotherapy in combination with chemotherapy (or without it) or targeted therapy. However, many conservative treatment modalities are accompanied by pronounced local or systemic toxic effects, which hinder completion of the planned therapy and, in some cases, result in patient death. Thus, the search for strategies to improve treatment outcomes in patients with advanced oropharyngeal cancer remains a relevant issue in oncology. Particular attention is given to the effectiveness of antitumor therapy in patients with human papillomavirus–associated oropharyngeal cancer.</p></abstract><trans-abstract xml:lang="ru"><p>В обзоре анализируются результаты терапии больных с местнораспространённым плоскоклеточным раком ротоглотки. Несмотря на применение современных высокотехнологичных методов, лечение этой категории пациентов остаётся сложной задачей. Эффективность того или иного подхода, как и при других злокачественных опухолях области головы и шеи в целом, зависит от множества факторов: стадии заболевания, локализации опухоли, методики лечения, наличия ВИЧ-инфекции и пр. Оперативные и реконструктивные методы большинству пациентов не показаны, что связано со сложной анатомической структурой орофарингеальной зоны и тяжёлым общим состоянием больных в силу запущенности процесса. Поэтому в большинстве случаев им показано консервативное лечение: лучевая терапия в комбинации с химиотерапией (или без таковой) или таргетной терапией. Однако многие консервативные методы сопровождаются выраженными местными или системными токсическими эффектами, что препятствует завершению запланированного лечения, а иногда является причиной смерти больных. Поэтому поиск путей улучшения результатов лечения пациентов с запущенными формами рака ротоглотки остаётся важной задачей в онкологии. В обзоре отдельно анализируется результативность противоопухолевой терапии больных раком ротоглотки, инфицированных вирусом папилломы человека.</p></trans-abstract><kwd-group xml:lang="en"><kwd>oropharyngeal squamous cell carcinoma</kwd><kwd>radiotherapy</kwd><kwd>chemoradiotherapy</kwd><kwd>HPV-positive oropharyngeal cancer</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>плоскоклеточный рак ротоглотки</kwd><kwd>лучевая терапия</kwd><kwd>химиолучевая терапия</kwd><kwd>ВПЧ-положительный рак ротоглотки</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Kaprin AD, Starinskij VV, Shahzadova AO, editors. Malignant neoplasms in Russia in 2023 (morbidity and mortality). Moscow: Moscow Research Institute of Oncology named after P.A. Herzen; 2024. 262 p. (In Russ.)</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>MakKregar S, Kraus RB, Balm AJ, et al. Carcinoma of the soft palate and the posterior oropharyngeal wall. Clin. Otolaryngol. 1994;19(1):22–27. doi: 10.1111/j.1365-2273.1994.tb01142.x</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Boyko AV, Gevorkov AR, Semin DYu. Oropharyngeal cancer. In: Kaprin AD, Mardynsky YuS, editors. National guidelines: Therapeutic radiology. Moscow: GEOTAR-Media Publishing Group; 2018:218–271. (In Russ.).</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Balkanov AS, Stepanova EA. The modern concept of using radiation therapy for cancer of the oral cavity and the oropharyngeal areathe modern concept of using radiation therapy for cancer of the oral cavity and the oropharyngeal area. Medical Radiology and Radiation Safety. 2020;65(1):65–71. doi: 10.12737/1024-6177-2020-65-1-65-71 EDN: RQBGFX</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Subramaniam N, Thankappan K, Anand A, et al. Implementing American Joint Committee on Cancer 8th edition for head-and-neck cancer in India: Context, feasibility, and practicality. Indian J Cancer. 2018;55(1):4–8. doi: 10.4103/ijc.IJC_475_17</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Trivedi S, Song H, Liu Y, et al. Comparison of the seventh and eighth editions of the American Joint Committee on Cancer (AJCC) staging for oropharyngeal squamous cell carcinomas (OPSCC): A Surveillance, Epidemiology and End Results Program (SEER) database analysis. Meeting Abstract: 2019 ASCO Annual Meeting I. Journal of Clinical Oncology. Abstract e17538. 2019;37(15 suppl). doi: 10.1200/JCO.2019.37.15_suppl.e17538</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Licitra L, Bernier J, Grandi C, et al. Cancer of the oropharynx. Crit Rev Oncol Hematol. 2002;41(1):107–122.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Gladilina IA, Shabanov MA, Nechushkin MI. Modern approaches to the treatment of oropharyngeal cancer. Practical Oncology. 2003;4(1):45–50. (In Russ.).</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Wong YF, Yusof MM, Wan Ishak WZ, et al. Treatment outcome for head and neck squamous cell carcinoma in a developing country: University Malaya Medical Centre, Malaysia from 2003–2010. Asian Pac J Cancer Prev. 2015;16(7):2903–2908. doi: 10.7314/apjcp.2015.16.7.2903</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Richardson PA, Kansara S3, Chen GG, et al. Treatment patterns in veterans with laryngeal and oropharyngeal cancer and impact on survival. Laryngoscope Investig Otolaryngol. 2018;3(4):275–282. doi: 10.1002/lio2.170</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Sher DJ, Adelstein DJ, Bajaj GK, et al. Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. Practical Radiation Oncology. 2017;7(4):246–253. doi: 10.1016/j.prro.2017.02.002</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>D’Сruz A, Lin T, Anand AK, et al. Consensus recommendations for management of head and neck cancer in Asian countries: a review of international guidelines. Oral Oncol. 2013;49(9):872–827. doi: 10.1016/j.oraloncology.2013.05.010</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Kurpeshev OK. Ways to improve the results of conservative therapy of malignant tumors of the head and neck organs. Part I. The current state of the issue (review). Russian journal of oncology. 2024;29(1):53–69. doi: 10.17816/onco630217 EDN: DABNPG</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Caudell JJ, Torres-Roca JF, Gillies RJ, et al. The future of personalised radiotherapy for head and neck cancer. Lancet Oncol. 2017;18(5):e266–273. doi: 10.1016/S1470-2045(17)30252-8</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Scott JG, Berglund A, Schell MJ, et al. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. Lancet Oncol. 2017;18(2):202–211. doi: 10.1016/S1470-2045(16)30648-9</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Studer G, Zwahlen RA, Graetz KW, et al. IMRT in oral cavity cancer. Radiation Oncology. 2007;2:16. doi: 10.1186/1748-717X-2-16</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Isaev PA, Medvedev VS, Pasov VV. Local radiation-induced injuries after radiation therapy and combined treatment of head and neck cancer. Radiation and risk. 2010;19(4):30–44. EDN: NREJGF</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Mak-Kregar S, Hilgers FJM, Levendag PC, et al. A nationwide study of the epidemiologist, treatment and survival of oropharyngeal carcinoma in the Netherlands. Europ. Arch. Oto Rhino Laryngology. 1995;252(3):133–138. doi: 10.1007/BF00178098</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Parsons JT, Mendenhall WM, Stringer SP, et al. Squamous cell carcinoma of the oropharynx: surgery, radiation therapy, or both. Cancer. 2002;94(11):2967–2980. doi: 10.1002/cncr.10567</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Moncharmont C, Vallard A, Guy JB, et al. Real-life efficacy of volumetric modulated arc therapy in head and neck squamous cell carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis. 2017;134(3):165–169. doi: 10.1016/j.anorl.2016.12.005</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Carvalho AL, Magrin J, Kowalski LP. Sites of recurrence in oral and oropharyngeal cancers according to the treatment approach. Oral Diseases. 2003;9(3):112–118. doi: 10.1034/j.1601-0825.2003.01750.x</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Olmi P, Crispino S, Fallai C, et al. Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy — a multicenter randomized trial. Int J Radiat Oncol Biol Phys. 2003;55(1):78–92. doi: 10.1016/s0360-3016(02)03792-6</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Fallai C, Bolner A, Signor M. et al. Long-term results of conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus concomitant radiotherapy and chemotherapy in locoregionally advanced carcinoma of the oropharynx. Tumori. 2006;92(1):41–54. doi: 10.1177/030089160609200108</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91(24):2081–2086. doi: 10.1093/jnci/91.24.2081</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004;22(1):69–76. doi: 10.1200/JCO.2004.08.021</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Parkhomenko LB, Krutilina NI. Treatment of advanced squamous cell head and neck cancer. Medical news. 2022;(7):26–32. EDN: YZVDLL</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Adelstein DJ. Oropharyngeal cancer: the role of chemotherapy. Curr Treat Options Oncol. 2003;4(1):3–13. doi: 10.1007/s11864-003-0027-6</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Ang KK, Harris J, Garden AS, et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. J Clin Oncol. 2005;23(13):3008–3015. doi: 10.1200/JCO.2005.12.060</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(27):2940–2950. doi: 10.1200/JCO.2013.53.5633</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>De Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180–e190. doi: 10.1016/S2214-109X(19)30488-7</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Gelwan E, Malm IJ, Khararjian A, et al. Nonuniform distribution of high-risk human papillomavirus in squamous cell carcinomas of the oropharynx: rethinking the anatomic boundaries of oral and oropharyngeal carcinoma from an Oncologic HPV perspective. Am J Surg Pathol. 2017;41(12):1722–8. doi: 10.1097/PAS.0000000000000929</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35. doi: 10.1056/NEJMoa0912217</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Castellsagué X, Alemany L, Quer M. ICO International HPV in Head and Neck Cancer Study Group. HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients. J Natl Cancer Inst. 2016;108(6):djv403. doi: 10.1093/jnci/djv403</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Chaturvedi AK, Graubard BI, Broutian T, et al. Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States. J Clin Oncol. 2018;36(3):262–7. doi: 10.1200/JCO.2017.75.0141</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Guo T, Kang SY, Cohen EEW. Current perspectives on recurrent HPV-mediated oropharyngeal cancer. Front. Oncol. 2022;12:966899. doi: 10.3389/fonc.2022.966899</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Naghavi AO, Strom TJ, Ahmed KA, et al. Management of Oropharyngeal Cancer in the HPV Era. Cancer Control. 2016;23(3):197–207. doi: 10.1177/107327481602300302</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma. Nature Reviews Disease Primers. 2020;6(1):92. doi: 10.1038/s41572-020-00224-3</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Chen AM. De-Escalation Treatment for Human Papillomavirus–Related Oropharyngeal Cancer: Questions for Practical Consideration. Oncology (Williston Park). 2023;37(7):281–287. doi: 10.46883/2023.25921000</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Allen CT, Lewis JS, El-Mofty SK, et al. Human papilloma virus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope. 2010;120(9):1756–1772. doi: 10.1002/lary.20936</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Schüttrumpf L, Marschner S, Scheu K, et al. Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck results from an unselected cohort of the clinical cooperation group “Personalized Radiotherapy in Head and Neck Cancer”. Radiation Oncology. 2020;15(1):7. doi: 10.1186/s13014-019-1452-4</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Petrelli F, Nardone M., Trevisan F, et al. Comparison of different treatments for HPV+ oropharyngeal carcinoma: a network meta-analysis. Eur Arch Otorhinolaryngol. 2023;280(3):963–971. doi: 10.1007/s00405-022-07710-2</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>O’Sullivan B, Huang SH, Su J, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016;17(4):440–510. doi: 10.1016/S1470-2045(15)00560-4</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Chera BS, Amdur RJ, Tepper JE, et al. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papilloma virus associated oropharyngeal squamous cell carcinoma. Cancer. 2018;124(11):2347–2354. doi: 10.1002/cncr.31338</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Chera BS, Amdur RJ, Green R, et al. Phase II trial of de-intensified chemoradiotherapy for human papilloma virus associated oropharyngeal squamous cell carcinoma. J Clin Oncol. 2019;37(29):2661–2669. doi: 10.1200/JCO.19.01007</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Seiwert TY, Foster CC, Blair EA, et al. OPTIMA: a phase II dose and volume deescalation trial for human papillomaviruspositive oropharyngeal cancer. Ann Oncol. 2019;30(2):297–302. doi: 10.1093/annonc/mdy522</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Marur S, Li S, Cmelak AJ, et al. E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx — ECOG-ACR In Cancer Research Group. J Clin Oncol. 2016;35(5):490–497. doi: 10.1200/JCO.2016.68.3300</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Cmelak A, Li S, Marur S, et al. Symptom reduction from IMRT dose deintensification: Results from ECOG 1308 using the Vanderbilt Head and Neck Symptom Survey version 2 (VHNSS V2). J Clin Oncol. 2015;33(15 suppl):6021a. doi: 10.1200/jco.2015.33.15_suppl.6021</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Misiukiewicz K, Gupta V, Miles BA, et al. Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial. Oral Oncol. 2019;95:170–177. doi: 10.1016/j.oraloncology.2019.06.021</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Tsai CJ, McBride SM, Riaz N, et al. Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus-Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy. JAMA Oncol. 2022;8(3):364–372. doi: 10.1001/jamaoncol.2021.6416</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Yang MQ, Liu YC, Sui JD, et al. Reduced-dose radiation in human papillomavirus-associated oropharyngeal carcinoma can improve outcome: a systematic review and meta-analysis. Ann Transl Med. 2022;10(24):1391. doi: 10.21037/atm-22-5935</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Hall SF, Liu FF, O’Sullivan B, et al. Did the addition of concurrent chemotherapy to conventional radiotherapy improve survival for patients with HPV+ve and HPV-ve Oropharynx cancer? A population-based study. Br J Cancer. 2017;117(8):1105–1112. doi: 10.1038/bjc.2017.275</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Saprina OA. Treatment strategy for HPV-positive oropharyngeal cancer: a literature review. Head and Neck Tumors. 2022;12(2):108–115. doi: 10.17650/2222-1468-2022-12-2-108-115 EDN: WHWKYZ</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Deschuymer S, Mehanna H, Nuyts S. Toxicity Reduction in the Treatment of HPV Positive Oropharyngeal Cancer: Emerging Combined Modality Approaches. Front Oncol. 2018;8:439. doi: 10.3389/fonc.2018.0043</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Lemeshko AM, Gevorkov AR, Boiko AV, et al. Individualization of treatment policy for patients with regional metastatic oropharyngeal carcinoma associated with human papillomavirus. P.A. Herzen Journal of Oncology. 2022;11(6):65–72. doi: 10.17116/onkolog20221106165 EDN: CFSWIV</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Machiels JP, Leemans CR, Golusinski W, et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2020;31(11):1462–1475. doi: 10.1016/j.annonc.2020.07.011</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Muzumder S, Nirmala S, Avinash HU, et al. Early competing deaths in locally advanced head-and-neck cancer. Indian J Palliat Care. 2018;24(4):446–450. doi: 10.4103/IJPC.IJPC_91_18</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Vivek RS, Baludavid M, Mohanram R, et al. Concurrent chemo-irradiation using accelerated concomitant boost radiation therapy in locoregionally advanced head and neck squamous cell carcinomas. J Cancer Res Ther. 2006;2(3):90–96. doi: 10.4103/0973-1482.27582</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Jehn P, Stier R, Tavassol F, et al. Physical and Psychological Impairments Associated with Mucositis after Oral Cancer Treatment and Their Impact on Quality of Life. Oncol Res Treat. 2019;42:342–348. doi: 10.1159/00049972</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Sher DJ, Adelstein DJ, Bajaj GK, et al. Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. Practical Radiation Oncology. 2017;7(4):246–253. doi: 10.1016/j.prro.2017.02.002</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Méry B, Guy JB, Espenel S, et al. Targeting head and neck tumoral stem cells: from biological aspects to therapeutic perspectives. World J Stem Cells. 2016;8(1):13–21. doi: 10.4252/wjsc.v8.i1.13</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA. 2007;104(3):973–978. doi: 10.1073/pnas.0610117104</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Sun Q, Chen X, Luo H, et al. Cancer stem cells of head and neck squamous cell carcinoma; distance towards clinical application; a systematic review of literature. Am J Cancer Res. 2023;13(9):4315–4345.</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Moncharmont C, Levy A, Gilormini M, et al. Targeting a cornerstone of radiation resistance: cancer stem cell. Cancer Lett. 2012;322(2):139–147. doi: 10.1016/j.canlet.2012.03.024</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Zisis V, Venou M, Poulopoulos A, Andreadis D. Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma — Treatment Modalities. Balk J Dent Med. 2021;73–79.</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Peltanova B, Raudenska M, Masarik M. Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: a systematic review. Molecular Cancer. 2019;18(1):1–24. doi: 10.1186/s12943-019-0983-5 EDN: SGERVC</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Bienkowska KJ, Hanley CJ, Thomas GJ. Cancer-Associated Fibroblasts in Oral Cancer: A Current Perspective on Function and Potential for Therapeutic Targeting. Front Oral Health. 2021;2:686337. doi: 10.3389/froh.2021.686337</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Kurpeshev OK, Pasov VV, Pilipenko AI, Ulasov GA. Metabolic modulation of the biological effects of ionizing radiation and chemotherapy (review). Russian Journal of Oncology. 2024;29(4):328–343. doi: 10.17816/onco635213 EDN: DMNTSA</mixed-citation></ref></ref-list></back></article>
